Carol is an adjunct professor within the Department of Microbiology, Immunology and Tropical Medicine of George Washington University.
Carol is a microbiologist by training and began her career at the Walter Reed Army Institute of Research in the USA where she studied the pathogenesis and immunologic regulation of infections caused by parasitic pathogens. She moved to industry to serve as Chief Scientific Officer for several US biotechnology companies in 1993 and founded Sequella, Inc. in 1997 to discover and develop novel antibiotics for the treatment of bacterial infections with global distribution. She has been the CEO of Sequella since 1999. Sequella has a novel antibiotic for tuberculosis (TB) which was discovered in-house and has successfully completed a phase 2b clinical trial.
She is on the Board of Directors of Rakta Therapeutics, which develops novel first-in-class antibiotics based on in vivo inhibition of heme acquisition in parasites. She has published over 160 peer-reviewed articles and book chapters and has been awarded several honours in both academia and industry. Carol is a member of the ASM Academy of Microbiology and is an editor of mBio, the official journal of the Academy.
Dr Carol A. Nacy
Sequella Inc., United States